Select a team member…
Don O’Neil VP of Commercial Operations
Don O’Neil brings over 20 years of sales and marketing experience in the life science sector that touches both instrumentation and consumable sales in therapeutics, sequencing and diagnostic markets. Upon completing his studies at UCSD with his MS in Mechanical Engineering, Don joined Illumina in 1998, contributing to building the company foundation in their next generation sequencing platform. Don then went on to pursue his MBA at Cornell, being named Kauffman Fellow/Venture Capital Associate and spent 2 years at Domain Associates, a noted VC firm based in San Diego. Through his VC experience, he continued to be excited about technology advancements in biotech, leading him to join Invitrogen and Millipore, where he led various Marketing leadership roles and later involved in the merger with Merck.
In 2012, Don joined Orflo as their Senior Vice President of Sales and Strategic Partnership, then joining Gemini Bio as their Chief Commercial Officer.
Don is passionate about evangelizing disruptive technology that has potential to change healthcare as it exists today and has a special interest in technology that can address and lead to better methods for understanding and treating mental illness. Don brings excitement and energy to the team which is well aligned with his hobbies: surfing and extreme fitness. He joined ONI in June 2021 as the VP of Commercial Operations and leads the Sales, Marketing, Field Application and Business Development teams.
Tyler Ralston CTO
Tyler Ralston, Ph.D. joined ONI in June 2021 as the Chief Technology Officer to innovate with the ONI team and further build out the amazing technology and applications. Using his deep technical knowledge around optical imaging technologies, Tyler has dedicated his career to find solutions for patient care to detect early signs of diseases.
Tyler has founded a number of companies and led the technical development work at Butterfly Network, that provides hand held ultrasound-on-chip imaging devices, Hyperfine, a breakthrough portable MRI machine, as well as Tesseract Health, developing portable retinal imaging systems. As an early founder, he has been instrumental in raising more than $400M in investment and seed funds, which has eventually led to a couple IPOs.
Prior to these accomplishments, he has been at Battelle, developing several award-winning instruments, including an automated microscope to detect cancer cells in pap tests, a gamma-ray detection console, and an automated white blood cell analysis microscope. Tyler continued his work across multiple modalities at Beckman Institute, MIT Lincoln Laboratory, and Lawrence Livermore National Laboratory, where he developed technologies and drove projects in 3D optical coherence tomography, multi-static 3D radar, 3D electro optic, and 3D gamma ray imaging. Tyler is an author and/or co-author of 100+ patents, 50+ papers with 4200+ citations, 3 book contributions with 42 presentations at international conferences, and 20+ invited presentations.
Tyler received his BS in Electrical and Computer Engineering at the University of Dayton, Ph.D. in Electrical and Computer Engineering at the University of Illinois at Urbana-Champaign.
Christine Nishiyama VP of Operations
Christine joined ONI in March 2021 as the Vice President of Operations, overseeing Customer Success, Supply Chain, Manufacturing, Quality, Program Management, IT and Facilities. She has a passion for building and developing top performing operations teams while driving customer success through cross functional collaboration.
Over her career, Christine has been engaged in strategic planning, ERP implementation, outsource contract manufacturing, and business development across all sectors of life science. Prior to joining ONI, she held the position of Director of Operations, Service & Support at Berkeley Lights, where she built the global field application and service organization while being a key contributor to the Operations team around supply chain and contract manufacturer NPI efforts. During her tenure, the company grew to >$70M in annual revenue and had a successful IPO in June 2020.
Prior to that she held various positions in commercial roles in the optics and photonics field from business development to OEM sales which fostered her acumen for customer relationship management. She received a BA/BS in Electrical Engineering and Minor in Mathematics from the University of San Diego where she continues to be an active member of the alumni community, as well as engaged in community college philanthropy work to foster the development of future educators.
Bo Jing CEO
Bo Jing is ONI’s CEO. Before co-founding ONI in 2016, Bo pursued a PhD in Physics at the University of Oxford and studied Mathematics (BSc) and Interdisciplinary Natural Sciences (MSc) at ETH Zurich.
Bo is passionate about democratizing life science tools and knowledge. He was born in China, grew up in Germany, studied in Switzerland, co-founded ONI in the UK and now lives in San Diego. He is also an avid Star Trek fan.
Sophia Mowla Chief Growth Officer
Sophia joined ONI in January 2022 as Chief Growth Officer overseeing People, Talent, Investor Relations & Comms and contributing to business development and overall growth strategy. Sophia also co-leads ONIs UK site.
Prior to ONI, Sophia built the life sciences practice at True Search in the space of two years, the 7th largest and fastest growing executive search firm in North America, initially leading the International Life Sciences practice and eventually, co-heading the Global practice with a team of 40 FTE. At True, Sophia worked with the top tier life science and tech investors and founders, collaborating with True equity to invest in high growth companies including ONI.
Sophia was also a key member of the Global Healthcare practice at Russell Reynolds Associates, working with fortune 500 pharmaceutical and Life Science companies on executive search, leadership and succession. She also has a track record in venture capital & private equity and a deep passion for transformational technology; she has placed CEOs/Chairs for a number of investor backed companies that have since gone through successful exit. Her portfolio includes devising boards for companies pre-IPO, which have then listed on the FTSE 100 & Fortune 500.
Sophia is a published scientist, she holds a First Class Master’s degree from University College London in Natural Sciences, specializing in Cell & Molecular Biology and Science Communication. She went on to start a PhD at Imperial College London, obtaining an MRC-funded scholarship in translational oncology using the latest cutting edge CRISPR/Cas9 genetic editing technology for the discovery of novel cancer therapeutics. During her PhD, she opened her own consultancy advising funds on pre-deal due-diligence and business development and still continues advising founders and investors on company creation in biotech given her passion for both ‘people’ and innovation in science. Given her mixed Mediterranean and Southern – Asian background, she enjoys experiencing, embracing and bridging cultures.
Sophia believes that at the heart of every decision is people. She is therefore building a strategic network of thought leaders that can help ONI realise its mission. Her biggest passion is having some input into making the world a better place, especially for her two daughters, one of which already considers herself a scientist at the age of four.
Ricardo Nunes Bastos Director of Business Development
Ricardo Bastos joined ONI in September 2017 and held various roles during his tenure including Senior application scientist, Head of Sales and now leads ONI’s growing Business Development team across the globe and co-leads ONI’s UK site. Ricardo was born in South Africa, lived in Portugal where he did his undergraduate degree in Biochemistry from the University of Porto before moving to Helsinki to do his PhD in Biotechnology. He then moved to the UK, to join the University of Oxford where he was curious and interested in better understanding what regulates membrane trafficking and how cells divide during mitosis. He holds 18 publications across 5 major journals including Journal of Cell Biology and Dev Cell.
Ricardo utilizes his deep insight from his PhD and Postdoc studies, for developing new product and application verticals that accesses ONI’s super resolution technology, to tackle the problems that keep him up at night. Through his own unwavering curiosity, he has developed a strong foothold across the ONI customer base. His main motivations are to enable all scientists independent of their background to explore the beautiful world of microscopy.